A Win For Seelos Therapeutics, Inc.
Seelos Therapeutics, Inc. (SEEL:NASDAQ) rocketted at $0.3, a gain of 57.4%. On Tue, Sep 24, 2024, SEEL:NASDAQ hit a New 2-Week High of $0.3. The stock appeared on our News Catalysts scanner on Tue, Sep 24, 2024 at 10:52 AM in the 'AGREEMENT' category. From Tue, Sep 10, 2024, the stock recorded 30.00% Up Days and 18.18% Green Days
The stock spiked on Tue, Sep 24, 2024 at $0.55 with a volume of 333M+.
About Seelos Therapeutics, Inc. (SEEL:NASDAQ)
Apricus Biosciences Inc is engaged in the pharmaceutical industry. The company develops and commercializes products and product candidates in the areas of urology and rheumatology. Apricus' drug delivery technology is a permeation enhancer called NexACT. The company has over two product candidates in Phase II development, fispemifene for the treatment of symptomatic male secondary hypogonadism and RayVa for the treatment of Raynaud's phenomenon.
Top 10 Gainers:
- BOQI International Medical Inc. (BIMI:NASDAQ), 650%
- Maison Solutions Inc. (MSS:NASDAQ), 115.86%
- Banzai International, Inc. Class A Common Stock (BNZI:NASDAQ), 96.19%
- XChange TEC.INC American Depositary Shares (XHG:NASDAQ), 93.55%
- Tempo Automation Holdings Inc. (TMPO:NASDAQ), 84.62%
- Seelos Therapeutics, Inc. (SEEL:NASDAQ), 57.37%
- Wave Life Sciences Ltd. (WVE:NASDAQ), 53.37%
- Capricor Therapeutics, Inc. (CAPR:NASDAQ), 52.43%
- DigiAsia Corp. (FAAS:NASDAQ), 47.86%
- Heart Test Laboratories, Inc. (HSCS:NASDAQ), 44.56%